There has been a resurgence of strong cannabis stock performance over the last few months due to renewed hope that the U.S. will reschedule cannabis and better company fundamentals. Investors have not wasted time rewarding firms that project actual improvement, and Tilray Brands (TLRY) is set to be a big winner.
Tilray announced strong Q1 earnings on Thursday, Oct. 9, and sparked frenzy throughout the cannabis industry. The management underscored profitable expansion in all three divisions (cannabis, beverages, and wellness), and its shares shot up sharply following the announcement. Tilray is proving to be one of the more stable companies within an otherwise unstable market, owing to its growing international sales and cost controls.
Let’s take a closer look to see whether Tilray’s strong earnings signal it’s time to rethink your portfolio strategy.
Based in Canada, Tilray is a global lifestyle consumer products company engaged in research, cultivation, processing, and distribution of medical cannabis products. The company’s product portfolio includes medical and adult-use cannabis, pharmaceutical and wellness products, beverages, and hemp-based food products.
Tilray’s stock has been extremely volatile this year. Early in 2025, TLRY was trading around $0.60 to $0.70, but it then rallied strongly to trade currently in the $1.70 range. Shares are up 29% in the year to date and an impressive 240% over the past six months.
Despite trading as a penny stock, Tilray has a premium valuation through several traditional measures. The cannabis and beverage company now commands a market capitalization of about $2 billion, supported by annual revenue of just over $820 million in 2024.
For instance, its adjusted forward price-to-earnings ratio of 53x remains elevated compared to the sector median of 17.5x, reflecting investor expectations for stronger profitability and growth ahead.
www.barchart.com
Tilray Brands reported a strong start to fiscal 2026, posting record first-quarter net revenue of $209.5 million, up…
..
